Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Pharma & Biotech